Clinical Trial Update: A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 dose- and efficacy-finding study evaluating RO5323441 in combination with bevacizumab in patients with recurrent glioblastoma; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Avastin (bevacizumab)
• RO5323441 (RO5323441)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Glioblastoma Multiforme | Phase 1 | Status: COMPLETED